Development of anticancer drugs targeting the MAP kinase pathway
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
ERK1b, a 46-kDa ERK Isoform That Is Differentially Regulated by MEK
Yung, Y., Yao, Z., Hanoch, T., & Seger, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m910060199 · Cited by 79
RetractedAlessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
Cowley, S. (1994) · Cell · doi:10.1016/0092-8674(94)90133-3 · Cited by 1,966
Signal Transduction through MAP Kinase Cascades
(1998) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60765-4 · Cited by 1,759
Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
Kölch, W. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510289 · Cited by 1,441
Transformation of Mammalian Cells by Constitutively Active MAP Kinase Kinase
Mansour, S. J., Matten, W. T., Hermann, A. S., Candia, J. M., Rong, S., Fukasawa, K., Vande Woude, G. F., & Ahn, N. G. (1994) · Science · doi:10.1126/science.8052857 · Cited by 1,353
Protein kinase Cα activates RAF-1 by direct phosphorylation
Kolch, W., Heidecker, G., Kochs, G., Hummel, R., Vahidi, H., Mischak, H., Finkenzeller, G., Marmé, D., & Rapp, U. R. (1993) · Nature · doi:10.1038/364249a0 · Cited by 1,277
The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain
Marais, R., Wynne, J., & Treisman, R. (1993) · Cell · doi:10.1016/0092-8674(93)90237-k · Cited by 1,275
Anderson, N. G., Maller, J. L., Tonks, N. K., & Sturgill, T. W. (1990) · Nature · doi:10.1038/343651a0 · Cited by 1,063
Cited by
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Mitogen-activated protein kinases in apoptosis regulation
Wada, T., & Penninger, J. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207556 · Cited by 1,432
The MAPK signalling pathways and colorectal cancer
Fang, J. Y., & Richardson, B. C. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70168-6 · Cited by 1,185
The role of focal-adhesion kinase in cancer — a new therapeutic opportunity
McLean, G. W., Carragher, N. O., Avizienyte, E., Evans, J., Brunton, V. G., & Frame, M. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1647 · Cited by 1,039
Multi-targeted therapy of cancer by genistein
Banerjee, S., Li, Y., Wang, Z., & Sarkar, F. H. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.052 · Cited by 620
Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70270-x · Cited by 552
Clinical proteomics: translating benchside promise into bedside reality
Petricoin, E. F., Zoon, K. C., Kohn, E. C., Barrett, J. C., & Liotta, L. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd891 · Cited by 550
Development of TGF-β signalling inhibitors for cancer therapy
Yingling, J. M., Blanchard, K. L., & Sawyer, J. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1580 · Cited by 549
Issues and progress with protein kinase inhibitors for cancer treatment
Dancey, J., & Sausville, E. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1066 · Cited by 526
Frank-Kamenetsky, M., Zhang, X. M., Bottega, S., Guicherit, O., Wichterle, H., Dudek, H., Bumcrot, D., Wang, F. Y., Jones, S., Shulok, J., et al. (2002) · Journal of Biology · doi:10.1186/1475-4924-1-10 · Cited by 488
Raf proteins and cancer: B-Raf is identified as a mutational target
Mercer, K. E., & Pritchard, C. A. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00016-7 · Cited by 457
Pharmacological inhibitors of MAPK pathways
English, J. M., & Cobb, M. H. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01865-4 · Cited by 447
Distinct requirements for Ras oncogenesis in human versus mouse cells
Hamad, N. M., Elconin, J. H., Karnoub, A. E., Bai, W., Rich, J. N., Abraham, R. T., Der, C. J., & Counter, C. M. (2002) · Genes & Development · doi:10.1101/gad.993902 · Cited by 431
LoRusso, P. M., Adjei, A. A., Varterasian, M., Gadgeel, S., Reid, J., Mitchell, D. Y., Hanson, L., DeLuca, P., Bruzek, L., Piens, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.415 · Cited by 401
Self-citationCancer: A Systems Biology disease
Hornberg, J. J., Bruggeman, F. J., Westerhoff, H. V., & Lankelma, J. (2006) · Biosystems · doi:10.1016/j.biosystems.2005.05.014 · Cited by 381
“The fact that kinase inhibitors are designed against targets that are mutated or overactive in cancer cells provides some intuitive confidence that they will be working more selectively against cancer cells than conventional chemotherapeutics ( Sebolt-Leopold, 2000 ).”
BackgroundMethodFocal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion
Carragher, N. O., & Frame, M. C. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.03.011 · Cited by 373
Infante, J. R., Somer, B. G., Park, J. O., Li, C.-P., Scheulen, M. E., Kasubhai, S. M., Oh, D.-Y., Liu, Y., Redhu, S., Steplewski, K., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.024 · Cited by 370
Effects of Raf Kinase Inhibitor Protein Expression on Suppression of Prostate Cancer Metastasis
Fu, Z., Smith, P. C., Zhang, L., Rubin, M. A., Dunn, R. L., Yao, Z., & Keller, E. T. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.12.878 · Cited by 364
The urokinase plasminogen activator system: a target for anti-cancer therapy
Ulisse, S., Baldini, E., Sorrenti, S., & D'Armiento, M. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909787314002 · Cited by 312
Schmitz, K. J., Wohlschlaeger, J., Lang, H., Sotiropoulos, G. C., Malago, M., Steveling, K., Reis, H., Cicinnati, V. R., Schmid, K. W., & Baba, H. A. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.08.018 · Cited by 309
Sheehan, K. M., Calvert, V. S., Kay, E. W., Lu, Y., Fishman, D., Espina, V., Aquino, J., Speer, R., Araujo, R., Mills, G. B., et al. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.t500003-mcp200 · Cited by 306
Kim, G.-Y., Kim, K.-H., Lee, S.-H., Yoon, M.-S., Lee, H.-J., Moon, D.-O., Lee, C.-M., Ahn, S.-C., Park, Y. C., & Park, Y.-M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.8116 · Cited by 306
BRAF mutations in papillary carcinomas of the thyroid
Fukushima, T., Suzuki, S., Mashiko, M., Ohtake, T., Endo, Y., Takebayashi, Y., Sekikawa, K., Hagiwara, K., & Takenoshita, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206739 · Cited by 297
Huynh, H., Nguyen, T. T. T., Chow, K.-H. K.-P., Tan, P. H., Soo, K. C., & Tran, E. (2003) · BMC Gastroenterology · doi:10.1186/1471-230x-3-19 · Cited by 289
Smith, J. A., Poteet-Smith, C. E., Xu, Y., Errington, T. M., Hecht, S. M., & Lannigan, D. A. (2005) · Cancer Research · doi:10.1158/0008-5472.1027.65.3 · Cited by 284
Mohi, M. G., Williams, I. R., Dearolf, C. R., Chan, G., Kutok, J. L., Cohen, S., Morgan, K., Boulton, C., Shigematsu, H., Keilhack, H., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.010 · Cited by 277
GnRH signaling, the gonadotrope and endocrine control of fertility
Bliss, S. P., Navratil, A. M., Xie, J., & Roberson, M. S. (2010) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2010.04.002 · Cited by 259
“The ability of ERKs to mediate the proliferative effects of RTK ligands has been demonstrated in a variety of settings, and has been the focus of intense investigation in the areas of basic cell biology as well as drug discovery and anti-cancer therapeutics [230,249].”
CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK)
ALLEN, L. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.012 · Cited by 257
Loss of HSulf-1 Up-regulates Heparin-binding Growth Factor Signaling in Cancer
Lai, J., Chien, J., Staub, J., Avula, R., Greene, E. L., Matthews, T. A., Smith, D. I., Kaufmann, S. H., Roberts, L. R., & Shridhar, V. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302203200 · Cited by 252
Mohi, M. G., Boulton, C., Gu, T.-L., Sternberg, D. W., Neuberg, D., Griffin, J. D., Gilliland, D. G., & Neel, B. G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400063101 · Cited by 239
Hou, D.-X., & Kumamoto, T. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2816 · Cited by 207
“The MAPK pathway consists of a three-tiered kinase core where a MAP3K ( e.g ., Raf ) activates a MAP2K ( e.g., MEK1 = 2) that activates a MAPKs ( e.g., ERK, JNK, and p38), resulting in the activation of NF-k B and AP-1 with cell growth and cell survival (180, 182).”
Zhang, Z., Teruya, K., Eto, H., & Shirahata, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027441 · Cited by 167
Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity
Reddy, N. S., Mallireddigari, M. R., Cosenza, S., Gumireddy, K., Bell, S. C., Reddy, E. P., & Reddy, M. V. R. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.05.016 · Cited by 165
Apoptosis inducing activity of fucoidan in HCT-15 colon carcinoma cells
Hyun, J.-H., Kim, S.-C., Kang, J.-I., Kim, M.-K., Boo, H.-J., Kwon, J.-M., Koh, Y.-S., Hyun, J.-W., Park, D.-B., Yoo, E.-S., et al. (2009) · Biological & Pharmaceutical Bulletin · doi:10.1248/bpb.32.1760 · Cited by 150
Callaway, K., Waas, W. F., Rainey, M. A., Ren, P., & Dalby, K. N. (2010) · Biochemistry · doi:10.1021/bi100199q · Cited by 32
Metadata
- Authors
- Sebolt-Leopold, J. S.
- Venue
- Oncogene
- Published
- 2000-12-27
- Volume
- 19
- Issue
- 56
- Pages
- 6594-6599
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2056031476
- Cited by
- 320
- References
- 64
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.